Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment
Open Access
- 1 January 2017
- journal article
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 22, 197-202
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Why First-Line Nivolumab Is No Better than ChemoCancer Discovery, 2017
- Cost analysis of adverse events associated with non-small cell lung cancer management in FranceClinicoEconomics and Outcomes Research, 2017
- Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectivesOncoTargets and Therapy, 2017
- Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicitiesOncotarget, 2017
- Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case seriesRespiratory Medicine Case Reports, 2017
- New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their managementCritical Care, 2017
- Targeted Lung Cancer Treatments and Eye Metastasis2017
- Tyrosine Kinase Inhibitors for the ElderlyJournal of Cancer, 2016
- Radial Endobronchial Ultrasound (EBUS) Guided Suction Catheter-Biopsy in Histological Diagnosis of Peripheral Pulmonary LesionsJournal of Cancer, 2016
- PET/CT versus MRI for diagnosis, staging, and follow-up of lung cancerJournal of Magnetic Resonance Imaging, 2014